Orlistat combined with everolimus suppresses pancreatic neuroendocrine tumor progression via inhibiting PI3K/AKT/mTOR signaling mediated by SLFN5
Endocrine-Related Cancer · 01.06.2026 · 33 (6)
DOI: 10.1530/erc-25-0422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 20.05.2026. Verfasst von Lin Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Orlistat, Pancreatic Neoplasms, Everolimus, Neuroendocrine Tumors. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Pancreatic neuroendocrine tumors (PanNETs) are characterized by limited therapeutic options and frequent resistance to monotherapies such as everolimus. Targeting metabolic pathways alongside mTOR signaling may improve treatment efficacy. This study aimed to investigate the synergistic antitumor effects of orlistat, a fatty acid synthase inhibitor, combined with everolimus in PanNETs and to elucidate the underlying molecular mechanisms. In vitro assays, including CCK-8, colony formation, EdU incorporation, and western blotting, were performed on PanNET cell lines. In vivo efficacy and safety were evaluated using subcutaneous xenograft mouse models. Transcriptomic profiling and functional studies of SLFN5 were conducted to uncover its regulatory role in PI3K/AKT/mTOR signaling and drug response. Orlistat and everolimus exhibited a significant synergistic inhibitory effect on PanNET cell proliferation. The combination markedly suppressed tumor growth in vivo without evident toxicity. RNA sequencing revealed distinct transcriptomic changes and highlighted SLFN5 as a key downregulated gene in PanNETs. Functional assays demonstrated that SLFN5 overexpression inhibited tumor growth and enhanced drug sensitivity by negatively regulating the PI3K/AKT/mTOR pathway. Conversely, SLFN5 knockdown impaired the antitumor efficacy of the drug combination. In conclusion, the combination of orlistat and everolimus represents a promising therapeutic strategy for PanNETs, with SLFN5 serving as a critical mediator and potential biomarker for treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroendocrine Tumor, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Gastroenterology, Xuzhou Medical University Jiangyin Clinical College, Jiangyin People's Hospital, Wuxi, Jiangsu, China.
- Department of Gastroenterology, Xishan People's Hospital of Wuxi City, Wuxi, Jiangsu, China.
ORCID-Profile: Jianan Bai, Mujie Ye, Qiyun Tang
Zitieren
APA
Xu, L., Liu, P., Chen, F., Tian, Y., Yan, L., Bai, J., Han, X., Long, Q., Li, X., Liu, M., Ye, M., & Tang, Q. (2026). Orlistat combined with everolimus suppresses pancreatic neuroendocrine tumor progression via inhibiting PI3K/AKT/mTOR signaling mediated by SLFN5. Endocrine-Related Cancer, 33(6). https://doi.org/10.1530/erc-25-0422
Vancouver
Xu L, Liu P, Chen F, Tian Y, Yan L, Bai J, et al. Orlistat combined with everolimus suppresses pancreatic neuroendocrine tumor progression via inhibiting PI3K/AKT/mTOR signaling mediated by SLFN5. Endocrine-Related Cancer. 2026;33(6). doi:10.1530/erc-25-0422
BibTeX
@article{Xu2026,
author = {Xu, Lin and Liu, Pengfei and Chen, Fengjuan and Tian, Ye and Yan, Lijun and Bai, Jianan and Han, Xu and Long, Qin and Li, Xiaoya and Liu, Min and Ye, Mujie and Tang, Qiyun},
title = {Orlistat combined with everolimus suppresses pancreatic neuroendocrine tumor progression via inhibiting PI3K/AKT/mTOR signaling mediated by SLFN5},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {6},
doi = {10.1530/erc-25-0422}
}
EUVIMED